Advanced Search: Sarcoma

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201203042

Tissue and Blood Acquisition for Genomic Analysis and Collection of Health Information for Patients with Bone and Soft Tissue Sarcoma: The Sarcoma Oncology Group

201601048

Phase 1 study evaluating combination therapy with the receptor tyrosine kinase inhibitor Turalio® (Pexidartinib (PLX3397) and Sirolimus in patients with unresectable sarcoma and Phase 2 study in malignant peripheral nerve sheath tumors.

201704120

A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity

201709159

A Phase III Study of AL3818 (Catequentinib,Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

201904069

Induction Paclitaxel followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma

201904129

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-Targeting Human Antibody-Cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-Line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

201904212

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)

201905136

Protocol J1S-MC-JAAA CAMPFIRE: Childrens and Young Adult Master Protocol for Innovative Pediatric Research

201906040

A PHASE 1b STUDY OF PTC596 IN COMBINATION WITH DACARBAZINE IN PATIENTS WITH LOCALLY RECURRENT, UNRESECTABLE OR METASTATIC RELAPSED/REFRACTORY LEIOMYOSARCOMA

201907126

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors